LASA vs NATCOPHARM: Stock Comparison
NATCO PHARMA is the larger company by market capitalisation. LASA shows faster revenue growth, while NATCO PHARMA shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LASA leads 2; NATCOPHARM leads 8 of 10
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LASA | NATCOPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LASA | NATCOPHARM |
|---|---|---|
| Live Price | ₹6.52 | ₹815.35 |
| Day Change | -2.54% | -0.4% |
| Volume | 46,913 | 5.68 L |
| 52-Week High | ₹14.08 | ₹1,226.8 |
| 52-Week Low | ₹5.67 | ₹789 |
| Distance from 52W High | -53.69% | -33.54% |
Valuation
| Metric | LASA | NATCOPHARM |
|---|---|---|
| Market Cap | ₹33 Cr | ₹14,669 Cr |
| P/E Ratio | — | 12.82x |
| P/B Ratio | — | 1.59x |
| EPS | ₹-0.71 | ₹11.53 |
| Book Value | ₹9.9 | ₹514.83 |
| Dividend Yield | 0% | 0.55% |
Growth
| Metric | LASA | NATCOPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -39.6% |
| EPS Growth (TTM YoY) | 0% | -34.1% |
| Qtr Sales Growth | — | 23.23% |
| Qtr Profit Growth | 14.06% | 176.81% |
Profitability & Leverage
| Metric | LASA | NATCOPHARM |
|---|---|---|
| ROE | -68.7% | 14.98% |
| ROCE | -57.92% | 14.19% |
| Net Margin | -135.6% | 34.78% |
| Operating Margin | -136.12% | 38.85% |
| Debt to Equity | 0.2x | 0.08x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | LASA | NATCOPHARM |
|---|---|---|
| Promoter Holding | 53.65% | 49.14% |
| FII Holding | 0% | 16.99%▼ 0.38 pp |
| DII Holding | 0% | 5.62%▲ 0.16 pp |
| Public Holding | 46.35% | 27.97%▲ 0.22 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LASA and NATCO PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.